“Amgen strives to serve patients by transforming the promise of science and biotechnology into therapies that have the power to restore health or save lives. In everything we do, we aim to fulfill our mission to serve patients. And every step of the way, we are guided by the values that define us.”
Amgen Inc., the organization this committee is the political fund of, amgen.com
CauseHealth care
Quoted from the committee's site, or its sponsor's or funder's where its own says nothing. The statement is filed under topics from a fixed list, chosen by AI models when two of three agree; which side it takes is in its own words.
No published list of positions
Its sponsor’s site sums up what it stands for in the statement above, and publishes no list of positions beyond it.
Who it gives toWhich candidates and committees get its money?
Each part reads different filings, so counts and totals can differ.
Party support distribution$762K to 201 candidates
Direct PAC contributions and independent expenditures explicitly reported as support, by the party of the candidate they went to.
For candidates $762,000
Republican 54%Democratic 34%
Support by the party of the candidate
Party of the candidate
Candidates
Direct
Independent
Amount
Share
Republican
85
$413,500
$0
$413,500
54%
Democratic
84
$256,500
$0
$256,500
34%
Other or unresolved
32
$92,000
$0
$92,000
12%
Shown support
201
$762,000
$0
$762,000
100%
Contributions are reported money, not endorsements; a PAC giving to both parties is common.
Who this PAC gave to$1,436,000 in 586 payments
Every contribution on line 23 of the committee’s own Schedule B, which is the filing its summary totals are built from. That line covers federal candidates, party committees and other political committees alike, so a super PAC funding other super PACs appears here rather than under candidate giving.
By recipient
Line 23 contributions by kind and party of recipient
Recipient
Count
Amount
Democratic candidates
86
$258.5K · 18%
Republican candidates
84
$411K · 29%
Other or unresolved candidates
33
$94.5K · 6.6%
Democratic party committees
1
$5K · 0.3%
Other party committees
3
$90K · 6.3%
Other PACs and committees
98
$579K · 40%
All recipients
305
$1.4M
By the candidate’s state
Contributions to candidates by the candidate’s state
State
Candidates
Amount
California
26
$98K
Texas
12
$50K
Florida
11
$46K
North Carolina
7
$37K
Ohio
8
$36.5K
New York
9
$33K
Pennsylvania
9
$32K
Washington
Show candidate activity and the money network
Candidate and election activity as the recipients filed it
Money inWho funds the PAC?
Where the money came from $1,346,744 reported receipts
Itemized (over $200)Donors who have given more than $200 this cycle, so the FEC itemizes (names) them.$1,154,17086%
Largest donors
Amy S. Kimball10 contributions, latest May 31, 2026 · DIRECTOR · AMGEN INC. · THOUSAND OAKS, CA$10,000
James Ellio Bradner6 contributions, latest Mar 31, 2026 · EXECUTIVE · AMGEN INC. · THOUSAND OAKS, CA$9,999
Robert A. Bradway4 contributions, latest Feb 28, 2026 · EXECUTIVE · AMGEN INC. · THOUSAND OAKS, CA$9,998
Jonathan P. Graham8 contributions, latest Apr 30, 2026 · EXECUTIVE · AMGEN INC. · THOUSAND OAKS, CA$9,998
Peter Griffith8 contributions, latest Apr 30, 2026 · EXECUTIVE · AMGEN INC. · THOUSAND OAKS, CA$9,998
Mark J. Taisey14 contributions, latest Jul 31, 2026 · EXECUTIVE · AMGEN INC. · THOUSAND OAKS, CA$9,998
Murdo Gordon7 contributions, latest Mar 31, 2026 · EVP GLOBAL COMMERCIAL OPS · AMGEN INC. · THOUSAND OAKS, CA$9,997
Margaret Chu-Moyer16 contributions, latest Aug 31, 2026 · EXECUTIVE · AMGEN INC. · THOUSAND OAKS, CA$9,996
Derek Miller12 contributions, latest Jun 30, 2026 · EXECUTIVE · AMGEN INC. · THOUSAND OAKS, CA$9,995
Sean Bruich10 contributions, latest May 31, 2026 · EXECUTIVE · AMGEN INC. · THOUSAND OAKS, CA$9,994
Howard Yuan- Chang8 contributions, latest Apr 30, 2026 · EXECUTIVE · AMGEN INC. · THOUSAND OAKS, CA$9,994
A donor who gave several times appears once. The 12 largest donors by total given are listed. In all, 5,710 itemized contributions were filed this cycle, totaling $1.1M. FEC contributor lists are public records and cannot be used for commercial solicitation.
Unitemized ($200 or less)Donors who have given $200 or less this cycle, so the FEC does not itemize (name) them.$160,51512%
Refunds and rebatesMoney coming back to the committee: rebates and refunds of what it spent, contributions it made that were returned, and loans it made that were repaid.$32,0002.4%
Other receiptsInterest, dividends and other income the committee files on a line of its own.$58<0.1%
Total reported receipts $1,346,744
Every dollar the committee reported receiving this cycle, split by the source the FEC filing attributes it to. Open a source marked + to see who gave. FEC filings through Oct 14, 2026.
Who donated: where they live, their employers and jobs
Where the donors live $1,087,452 placed by state
Loading the map
Tap or hover over a state, or focus the map and use the arrow keys, to read its total. Ctrl or ⌘ and scroll to zoom.
under $43.5K
$43.5K+
$174K+
$391.5K+
$696K+
none
Top states
Top donor states
Name
Amount
California5,710 contributions · 100%
$1,087,452
By the state each contributor wrote on the filing. The FEC aggregates every Schedule A line together, so one committee or organization transfer can account for a whole state. Contributors who have given $200 or less this cycle are not itemized and cannot be placed on a map. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total.
Donors’ employers as filed
Donors’ employers
Employer as filed
Amount
Amgen INC5,710 contributions · 100% of ranked
$1,087,452
Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($160,515) are not itemized, so no employer or occupation is filed for them.
Donors’ occupations as filed
Donors’ occupations
Occupation as filed
Amount
Executive991 contributions · 45% of ranked
SpendingWhere does the money go?
How the spending splits $1,551,500 reported
Contributions to candidates and other committeesMoney given to federal candidates, party committees and other PACs.$1,468,00095%
Paid to
NRCC4 payments · latest Jan 30, 2026 · CONTRIBUTION$30,000
NRSC2 payments · latest Jan 30, 2026 · CONTRIBUTION$30,000
DSCC2 payments · latest Feb 19, 2026 · CONTRIBUTION$30,000
Common Values PAC2 payments · latest Mar 26, 2026 · CONTRIBUTION$10,000
Equality PAC2 payments · latest Mar 26, 2026 · CONTRIBUTION$10,000
Other disbursementsEverything the committee reports outside the lines above.$83,5005.4%
Total reported disbursements $1,551,500
Every dollar this committee reported spending this cycle, split by the lines it reports against. Open a line to see who was actually paid on it. FEC filings through Oct 14, 2026.
What the payments were for $1,436,000 itemized
Given to othersContributions to other candidates, party committees, and PACs.$1,436,000100%
Filed as
CONTRIBUTION$1,436,000
Paid to
NRCC$30,000
NRSC$30,000
DSCC$30,000
Johnson Leadership Fund$30,000
Scalise Leadership Fund$15,000
Bringing Republican Excellence to Town PAC$10,000
Total itemized disbursements $1,436,000
Every itemized payment the committee reported this cycle, sorted by what it said each one was for. The categories are ours; the wording they are matched against is the committee’s own. Open a category to read the filed descriptions and who was paid. FEC filings through Oct 14, 2026.
All 586 itemized payments filed this cycle. Spending below the itemization threshold is not filed line by line.
$1.6M spent from Jan 2025 to Oct 2026. Most in one report: $256.5K, March 2026.
$1.6M
Jan 2025Oct 2026
The running total of what the committee’s FEC reports say it spent, independent expenditures included, with a point at the end of each report. The line is straight between reports because a report gives one total for its whole period.
Besides giving through its PAC, Amgen Inc. pays lobbyists to press Congress and federal agencies. Each quarter it, or a firm it hires, files a public report under the Lobbying Disclosure Act saying which topics it worked on, what it spent, and whom it contacted. This is what those reports say.
Spent on lobbying in 2026
$8.2M
Quarterly reports read
75 of 89
Bills it named
52
Topics it lobbied on
Each report files its work under official topics. The bar shows how often each topic came up across the reports; open one to read what was filed under it. Naming a bill says the organization lobbied on it, not which side it took.
Medicare/Medicaidin 38 report entries · 22 bills named
In its own words
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act (EPIC) HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to reimbursement for biologics/biosimilars Issues related to PBM reform Issues related to bone disease awareness and treatment S.3345, PBM Price Transparency and Accountability Act HR 6166, Lowering Drug Costs for American Families Act S 3019 - No Big Blockbuster Bailouts Act S 3349 PBM Disclosure Act HR 4317 PBM Reform Act Issues related to Public law 117-1769 Inflation Reduction Act HR 1672 Maintaining Investments in New Innovation Act (MINI) HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 PL 119-75 Consolidated Appropriations Act of 2026 HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act
Access and reimbursement for Part B and Part D drugs.
Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.
Issues related to physician reimbursement under Medicare Part B drugs, including H.R. 4299 -Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model
Issues related to drug pricing and reimbursement for prescription drugs;
Issues related to H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act;
Issues related to H.R. 5526/S. 1954, Biosimilar Red Tape Elimination Act;
Issues related To S. 5459, The Biosimilar Access and Affordability Act;
Issues related to Senate Finance Dear Colleague process
Issues related to Senate Finance Dear Colleague process;
H.R. 10628/S. 5571, Biosimilars Access and Affordability Act
Health Issuesin 37 report entries · 35 bills named
In its own words
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act HR 10628/ S 5571 Biosimilars Access and Affordability Act S 5244 Sustain 340B Act HR 9599 Secure 340B Act HR 5509/ S 2903 Safe Step Act
Taxation/Internal Revenue Codein 24 report entries · 2 bills named
In its own words
Issues related to corporate and international tax Public Law 115-97, Tax Cuts and Jobs Act Public Law 119-21, One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income
Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97);
Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169);
Issues related to the Medicaid Drug Rebate Program;
Issues related to the 340b program.
Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Tax issues related to the pharmaceutical industry. Implementation of PL 119-21.
Copyright/Patent/Trademarkin 14 report entries · 15 bills named
In its own words
Federal Trade Commission related issues Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS Issues related to patent thickets Issues related to obviousness/ double patenting Issues related to FDA/PTO coordination Issues related to skinny labeling S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE) S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL) S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA) S 2276 / HR 3269 Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 43/HR 6485 Skinny Labels Big Savings Act S.2658 Medication Affordability and Patent Integrity Act S. 3452/HR 6624 Biological Intellectual Property Protection Act of 2025
Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.
H.R.3160/S.1553: Promoting and Respecting Economically Viable American Innovation (PREVAIL) Act.
Budget/Appropriationsin 11 report entries · 2 bills named
In its own words
Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Appropriations. S.2: Secure America Act (Reconciliation 2.0). H.R.8800: National Defense Authorization Act for Fiscal year 2027.
Issues related to tariffs. Issues related to drug pricing.
Issues related to tariff and trade policy.
Issues related to tariffs.
Tariffs
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
Natl Economic Council (NEC)
Pharmacyin 6 report entries · 2 bills named
In its own words
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
H.R.1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of pharmaceuticals.
Issues related to prescription drug pricing and pharmacy benefit manager business practices.
Issues related to the 340B program.
Drug pricing and patient affordability. Issues related to 340B. Biosimilars reimbursement and regulatory standards. Issues related to Supply Chain. H.R.1672: Maintaining Investments in New Innovation (MINI) Act.
Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.
Educating members on issues affecting Amgen and patients
Biologics, biotechnology policies.
Offices it contacted
HOUSE OF REPRESENTATIVES
SENATE
From the 75 most recent of 89 reports, so a topic missing here may appear in an earlier one.
Who did the lobbying
The organization’s own reports give its total lobbying costs, including any firms it hired; each firm reports what this client paid it.
Matched by name: these reports are filed for “AMGEN INC.”, found by searching “AMGEN”. Lobbying and FEC records share no ID, so an organization that lobbies under another name is missed. Source: LDA.gov, accessed Oct 26, 2026. Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Amgen Inc. PAC is registered with the Federal Election Commission as a PAC (qualified). It is a lobbyist/registrant PAC. Its FEC record names Amgen Inc. as an affiliate. Official FEC summary: Federal Election Commission committee record.
Jon Husted3 receipts, latest Mar 26, 2026Husted for Senate · S6OH00304$10K
Scott Peters2 receipts, latest Mar 26, 2026Scott Peters for Congress · H2CA52089$10K
Candidate contribution rows come from candidate committee Schedule A filings, the same rows the party chart above counts.
Committee money network
Money moving between this committee and other committees, matched on FEC committee ID rather than the name each filing was typed under. Both sides exclude memo entries. The figures here count each committee once, from the itemized transfers read for this section, so they will not match the payment counts under Who this PAC gave to.
Committees funding this one
Committees that reported giving to this one on their own Schedule A filings, grouped by the giver’s committee ID.
Committees funding this one
Name
Amount
Mullin for AmericaSenate campaign committee · Connected to MULLIN VICTORY FUND · 1 payment
$1.5K
$1.5K from 1 committee, counting every itemized receipt this cycle.
Committees this one funds
Disbursements this committee itemized to another committee: candidate contributions, party transfers and payments alike, not contributions only.
$1.4M across 308 recipient committees, or 92% of everything this committee reports spending. The largest 12 are shown. A further $1K was filed as memo entries, which FEC reports separately to avoid counting it twice.
Built from FEC Schedule A and Schedule B filings for the selected cycle. A committee only appears here if the money was itemized under its FEC committee ID.
$485,325
Manager3,473 contributions · 30% of ranked
$326,114
Director1,198 contributions · 23% of ranked
$255,163
EVP Global Commercial OPS7 contributions · 0.9% of ranked
$9,997
VP Global Regulatory Affairs19 contributions · 0.8% of ranked
$9,224
Government Affairs Senior Manager16 contributions · 0.1% of ranked
$1,329
Senior Manager Government Affairs6 contributions · <0.1% of ranked
$300
Itemized receipts grouped by the words contributors filed. The FEC aggregates every Schedule A line here, so committee and organization money sits alongside individuals; this is not an industry classification. The FEC’s grouping also counts joint-fundraising memo lines, so these rows can add up to more than the itemized total. Gifts of $200 or less ($160,515) are not itemized, so no employer or occupation is filed for them.
The people, firms and committees paid the most, across every kind of payment. Each share is of everything the committee reported spending this cycle, not only the itemized payments above. A payee that is itself a committee links to its own profile.
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act H.R.5526 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act HR 7391 Community Health Center Drug Pricing Protection Act HR 8143/S 4323 Ensuring Access to Lower-Cost Medicines for Seniors Act S.2, Secure America Act (Reconciliation 2.0) S 3014 Ensuring Timely Access to Generics Act of 2025 S 2355 Patients Deserve Price Tags Act HR 8646 Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 HR 8800 National Defense Authorization Act for Fiscal year 2027 HR 9102 BINSA Bill COINS Act, enacted within P.L. 119-60 National Defense Authorization Act for Fiscal Year 2026 S 1414 Expedited Access to Biosimilars Act
Issues related to drug pricing Issues related to cardiovascular disease awareness and treatment Issues related to FDA Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Issues related to biosimilars reimbursement Issues related to Supply Chain Issues related to 340B Issues related to pharmacy benefit managers Issues related to biosimilars regulatory standards Issues related to bone disease awareness and treatment Issues related to Public law 117-1769 Inflation Reduction Act HR 1492 Ensuring Pathways to Innovative Cures Act HR 1672 Maintaining Investments in New Innovation Act HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14) S 1954 Biosimilar Red Tape Elimination Act S.3345 PBM Price Transparency and Accountability Act H.R. 6166 Lowering Drug Costs for American Families Act S.3019 No Big Blockbuster Bailouts Act HR 4317 PBM Reform Act S 3510 Biosimilar Inspection Modernization Act PL 119-75 Consolidated Appropriations Act of 2026 HR 4299 Protecting Patient Access to Cancer and Complex Therapies Act H.R.7837 Most Favored Patient Act of 2026 S 3788 Clear Labels Act HR 5256 340B Access Act H.R.5526 Biosimilar Red Tape Elimination Act HR 7391 Community Health Center Drug Pricing Protection Act
Issues related to pharmacy benefit management reforms.
Issues related to cardiovascular care.
Issues related to drug pricing.
Issues related to the drug supply chain.
S. 3788, Clear Labels Act.
S. 3014, Ensuring Timely Access to Generics Act of 2025;
S. 1954, Biosimilar Red Tape Elimination Act;
S. 2658, Medication Affordability and Patent Integrity Act.
Issues related to pharmacy benefit management.
General education about federal policies impacting pharmaceutical development, approval, and patient access. 340B, Policies impacting public health preparedness and prevention.
Policies impacting Cardiovascular and bone health.
Pharmacy benefit manager reform proposals.
FDA reform, prescription drug reimportation and new proposals.